Pulmokine Overview

  • Founded
  • 2007

Founded
  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 3

Pulmokine General Information

Description

Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders. The company's pulmonary disease and kinase inhibitor technology treats crucial lung conditions, enabling patients suffering from lung diseases to access pulmonary drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 7 University Place
  • Room B127
  • Rensselaer, NY 12144
  • United States
+1 (518) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pulmokine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 000 Completed Generating Revenue
5. Grant 01-Jan-2017 00000 000 Completed Generating Revenue
4. Grant 01-Jan-2016 00.000 000 Completed Generating Revenue
3. Seed Round 04-Mar-2015 000 000 Completed Generating Revenue
2. Debt - General 01-Oct-2014 Completed Generating Revenue
1. Grant 27-Mar-2014 $1.5M Completed Generating Revenue
To view Pulmokine’s complete valuation and funding history, request access »

Pulmokine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders.
Biotechnology
Rensselaer, NY
000
000000 - 000 000

0000 0

r adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad min
0000 000000000
Austin, TX
00 As of 0000
000.00
0000000000 0 000.00

000000

p ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dol
0000000000000
Mechelen, Belgium
0000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pulmokine Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lung Therapeutics Venture Capital-Backed Austin, TX 00 000.00 0000000000 0 000.00
000000000 (0000000 Formerly VC-backed Mechelen, Belgium 0000 00.000 000000000 00.000
000000 000000 Accelerator/Incubator Backed Morristown, NJ 0 00.000 000000000 00.000
00000000 000000000 Venture Capital-Backed Tucson, AZ 0 000.00 00000000000 000.00
000000000 00000000 Corporation Pasadena, CA 000 00.000 000000 - 000 00.000
You’re viewing 5 of 17 competitors. Get the full list »

Pulmokine Patents

Pulmokine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210038510-A1 Formulations of kinase inhibitors and prostanoids Pending 08-Feb-2018 0000000000
EP-3532063-A4 Combination therapy for treating pulmonary hypertension Pending 27-Oct-2016 0000000000 0
US-10231966-B2 Combination therapy for treating pulmonary hypertension Active 27-Oct-2016 0000000000 00
CA-3041679-A1 Combination therapy for treating pulmonary hypertension Pending 27-Oct-2016 0000000000
EP-3532063-A1 Combination therapy for treating pulmonary hypertension Pending 27-Oct-2016 A61K31/497
To view Pulmokine’s complete patent history, request access »

Pulmokine Executive Team (5)

Name Title Board Seat Contact Info
Lawrence Zisman Founder, Chief Executive Officer & President
Ron Wolff Ph.D Vice President of Regulatory Affairs and Toxicology
Aaron Waxman MD Scientific Advisor
Rubin Tuder MD Scientific Advisor
You’re viewing 4 of 5 executive team members. Get the full list »

Pulmokine Board Members (2)

Name Representing Role Since
Shreefal Mehta Ph.D Self Board Director 000 0000
You’re viewing 1 of 2 board members. Get the full list »

Pulmokine Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
U.S. Department of Health and Human Services Government 000 0000 000000 0
National Heart, Lung and Blood Institute Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
To view Pulmokine’s complete investors history, request access »